New drug combo targets Hard-to-Treat pancreatic tumors
NCT ID NCT05687123
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether combining two targeted therapies—sunitinib malate and Lutathera—is safe for people with advanced pancreatic neuroendocrine tumors that have spread or cannot be removed. Sunitinib blocks signals that help tumors grow, while Lutathera delivers radiation directly to tumor cells. The study will enroll 24 participants to find the best dose and watch for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sunitinib malate and lutetium Lu 177 dotatate (Lutathera)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced pancreatic neuroendocrine tumors.
What could go wrong
This is a very early Phase I trial with only 24 participants, so the main goal is safety, not effectiveness. The combination may cause significant side effects or may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGDuarte, California, 91010, United States
-
Memorial Hospital East
RECRUITINGShiloh, Illinois, 62269, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Siteman Cancer Center at Christian Hospital
RECRUITINGSt Louis, Missouri, 63136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Siteman Cancer Center at Saint Peters Hospital
RECRUITINGCity of Saint Peters, Missouri, 63376, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Siteman Cancer Center at West County Hospital
RECRUITINGCreve Coeur, Missouri, 63141, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Siteman Cancer Center-South County
RECRUITINGSt Louis, Missouri, 63129, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
RECRUITINGOrange, California, 92868, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
RECRUITINGIrvine, California, 92612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Health Network-Princess Margaret Hospital
ACTIVE_NOT_RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••